1. Home
  2. RVSN vs LGVN Comparison

RVSN vs LGVN Comparison

Compare RVSN & LGVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Rail Vision Ltd.

RVSN

Rail Vision Ltd.

N/A

Current Price

$2.38

Market Cap

7.9M

Sector

N/A

ML Signal

N/A

Logo Longeveron Inc.

LGVN

Longeveron Inc.

N/A

Current Price

$3.00

Market Cap

7.8M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
RVSN
LGVN
Founded
2016
2014
Country
Israel
United States
Employees
N/A
N/A
Industry
Medicinal Chemicals and Botanical Products
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.9M
7.8M
IPO Year
2018
2021

Fundamental Metrics

Financial Performance
Metric
RVSN
LGVN
Price
$2.38
$3.00
Analyst Decision
Analyst Count
0
0
Target Price
N/A
★ $61.25
AVG Volume (30 Days)
20.9K
★ 97.8K
Earning Date
08-26-2026
11-24-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 50.76
EPS
★ N/A
N/A
Revenue
N/A
★ $709,000.00
Revenue This Year
$169.00
$46.15
Revenue Next Year
N/A
$396.46
P/E Ratio
N/A
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$0.17
$0.48
52 Week High
$9.39
$7.60

Technical Indicators

Market Signals
Indicator
RVSN
LGVN
Relative Strength Index (RSI) 32.45 64.84
Support Level N/A $0.63
Resistance Level $3.52 $7.30
Average True Range (ATR) 0.26 0.24
MACD -0.03 0.23
Stochastic Oscillator 0.89 84.44

Price Performance

Historical Comparison
RVSN
LGVN

About RVSN Rail Vision Ltd.

Rail Vision Ltd is an early commercialization stage technology company focused on railway safety systems using AI-integrated sensing systems. The company develops and commercializes proprietary, multi-spectral electro-optic platforms that provide extended-range situational awareness and real-time hazard detection. Using machine learning algorithms to identify and classify obstacles, the company's technology enhances safety, improves operational efficiency, and supports continuity across deployments.

About LGVN Longeveron Inc.

Longeveron Inc is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. Its investigational product candidate is laromestrocel. Laromestrocel is a proprietary, scalable, allogeneic cellular therapy that has multiple potential modes of action that include pro-vascular, pro-regenerative, and anti-inflammatory mechanisms that collectively appear to promote tissue repair and healing. It is in clinical development of a single investigational product candidate, laromestrocel, for four potential indications: HLHS, Alzheimer's disease (AD), Pediatric Dilated Cardiomyopathy (pediatric DCM), and Aging-related Frailty. It operates in a single operating segment focused on developing regenerative medicines to address unmet medical needs.

Share on Social Networks: